COTA Research Recognized at ASH 2025: Advancing Real-World Evidence in Hematologic Malignancies

COTA’s scientific contributions have once again been recognized by the American Society of Hematology (ASH) Annual Meeting and Exposition, one of the most prestigious global forums for advancing hematology research.

This year, five studies using COTA’s real-world data (RWD) and coauthored by our research team were accepted for presentation—including COTA’s first-ever oral presentation at ASH. This milestone underscores the growing impact of COTA’s research, as oral presentations are reserved for studies demonstrating the highest level of scientific merit and clinical relevance.

Coauthored abstracts accepted for publication at ASH 2025:

1. Title: Real-world treatment patterns and outcomes of patients with myelodysplastic syndrome by line of therapy
   1. Presentation Type: Oral Presentation
   2. Disease: MDS
   3. Coauthors/Organizations:
      1. Diego Adrianzen Herrera¹, Jacob Ambrose², Andrew Belli², Eric Hansen², Christina Zettler², Laura Fernandes², Stephanie Wiley², Courtney Anderson², Ching-Kun Wang²
         1. University of Vermont Larner College of Medicine, Division of Hematology and Oncology, Burlington, VT, United States, 
         2. COTA, Inc., New York, NY, United States
   4. Abstract Summary: Limited real-world evidence exists on outcomes for patients with MDS who progress and require later lines of therapy. This study found that patients with high-risk disease at diagnosis and those progressing after initial treatments experience poor outcomes.

2. Title: Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation
   1. Presentation Type: Poster
   2. Disease: MDS
   3. Coauthors/Organizations:
      1. Diego Adrianzen Herrera¹, Jacob Ambrose², Andrew Belli², Eric Hansen², Christina Zettler², Laura Fernandes², Stephanie Wiley², Ming He², Ching-Kun Wang²
         1. University of Vermont Larner College of Medicine, Division of Hematology and Oncology, Burlington, VT, United States, 
         2. COTA, Inc., New York, NY, United States
   4. Abstract Summary: TP53 mutations occur in about 10% of patients with MDS and are associated with high-risk disease. Patients with TP53m showed significantly worse long-term outcomes compared to those with TP53wt.

3. Title: Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+)​ diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States
   1. Presentation Type: Poster
   2. Disease: DLBCL
   3. Coauthors/Organizations:
      1. Michael Wallington¹, Yong Chen², Fei Jie³, Monica Marie Patterson³, Karen Repetny³, Michelle Fanale³, Simon Purcell¹, Jacob Ambrose⁴, Christina Zettler⁴, Andrew J. Belli⁴, Laura L. Fernandes⁴, Ching-Kun Wang⁴
         1. Pfizer, Ltd., Walton Oaks, United Kingdom 
         2. Pfizer, Inc., Collegeville, PA, United States 
         3. Pfizer, Inc., Bothell, WA, United States
         4. COTA, Inc., New York, NY, United States​
   4. Abstract Summary: As more treatment options such as CAR-T therapy become available for patients with R/R DLBCL, estimating real-world survival for patients on standard care has become increasingly complex. This study shows that real-world data can effectively contextualize clinical trial results and underscores the need for new therapies for R/R DLBCL patients receiving third-line or later treatment who are ineligible for HSCT or CAR-T.

4. Title: R-miniCHOP preserves efficacy and limits toxicity compared to dose intense therapy and non-chemo options for older patients with DLBCL.
   1. Presentation Type: Poster
   2. Disease: DLBCL
   3. Coauthors/Organizations:
      1. Danielle Wallace¹, Claire Bai², Andrew Belli², Eric Hansen², Christina Zettler², Laura Fernandes2, StephanieWiley², Ching-Kun Wang², Paul Barr¹
         1. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States
         2. COTA, Inc., New York, NY, United States​
   4. Abstract Summary: In older or frail patients with DLBCL, R-mini-CHOP provided outcomes comparable to more intensive regimens with fewer treatment discontinuations from toxicity. Further dose-reduced regimens led to worse outcomes despite similar baseline characteristics.

5. Title: Real-world outcomes for anti-CD38 monoclonal antibody-naive and exposed patients receiving treatment for multiple myeloma
   1. Presentation Type: Poster
   2. Disease: MM
   3. Coauthors/Organizations:
      1. Ben Derman¹, Magnolia Watson², Jacob Ambrose², Christina Zettler², Andrew Belli², Laura L. Fernandes², Ming He²
         1. The University of Chicago, Section of Hematology/Oncology, Department of Medicine, Chicago, IL, United States
         2. COTA, Inc., New York, NY, United States
   4. Abstract Summary: In relapsed or refractory multiple myeloma, patients previously treated with anti-CD38 therapies had a shorter time to next treatment than anti-CD38–naive patients. Re-exposure to anti-CD38 antibodies did not improve outcomes compared with regimens without these agents.